Janumet XR (metformin; sitagliptin)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

☐ **URGENT**

MEMBER INFORMATION	
LAST NAME:	**FIRST NAME:**
PHONE NUMBER:	**DATE OF BIRTH:**
STREET ADDRESS:	
CITY:	**STATE:** **ZIP CODE:**
PATIENT INSURANCE ID NUMBER:	

☐ **MALE** ☐ **FEMALE** **HEIGHT (IN/CM):** _____ **WEIGHT (LB/KG):** _____ **ALLERGIES:** _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	**FIRST NAME:**
PRESCRIBER SPECIALTY:	**EMAIL ADDRESS:**
NPI NUMBER:	**DEA NUMBER:**
PHONE NUMBER:	**FAX NUMBER:**
STREET ADDRESS:	
CITY:	**STATE:** **ZIP CODE:**
REQUESTOR (if different than prescriber)**:**	**OFFICE CONTACT PERSON:**

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	**FREQUENCY:**	**LENGTH OF THERAPY/REFILLS:**	**QUANTITY:**
☐ **NEW THERAPY** ☐ **RENEWAL** DURATION OF THERAPY (SPECIFIC DATES):		**IF RENEWAL:** DATE THERAPY INITIATED:	

Continued on next page.

Revision Date: 10/01/2022

Prime THERAPEUTICS™

Janumet XR (metformin; sitagliptin)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? ☐ YES (if yes, complete below) ☐ NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE)**:**	**DURATION OF THERAPY** (SPECIFY DATES)**:**	**RESPONSE/REASON FOR FAILURE/ALLERGY:**

2. LIST DIAGNOSES:	**ICD-10:**
☐ Type 2 diabetes ☐ Type 1 diabetes ☐ Other Diagnosis_____ICD-10 Code(s):_____	

3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.

Is the patient 18 years of age or older? ☐ Yes ☐ No

Is the patient already taking the requested medication? ☐ Yes ☐ No

Is the patient's most recent hemoglobin A1c (HbA1c) 7% or greater (HbA1c must be taken within the past 6 months)? ☐ Yes ☐ No
Copy of HgbA1c level required.
Was the patient's most recent HbA1c level, PRIOR to STARTING the requested medication, 7.0% or greater? ☐ Yes ☐ No
Copy of HgbA1c level required.

Is the patient currently on metformin? ☐ Yes ☐ No
Please provide documentation.

Has the patient failed treatment with or had an intolerance to metformin? ☐ Yes ☐ No
Please provide documentation.

Does the patient have a true medical contraindication to metformin, defined as one of the following: ☐ Estimated glomerular filtration rate (GFR) less than or equal to 45 mL/min/1.73 m2 ☐ advanced liver disease with cirrhosis, portal hypertension, ascites, and/or hepatic encephalopathy? ☐ Yes ☐ No

Is the patient currently taking another DPP-4 inhibitor? (Please Circle)
- **Glyxambi (empagliflozin/linagliptin)**
- **Jentadueto/Jentadueto XR (linagliptin/metformin)**
- **Janumet/Janumet XR (sitagliptin/metformin)**
- **Nesina (alogliptin)**
- **Tradjenta (linagliptin)**
- **Januvia (sitagliptin)**
- **Onglyza (saxagliptin)**
- **Kombiglyze XR (saxagliptin/metformin)**
- **Oseni (alogliptin/pioglitazone)**
- **Kazano (alogliptin/metformin)**

Will the other DPP-4 inhibitor be discontinued? □ Yes □ No

Is the patient currently taking any of the following medications? (Please Circle)
- **Trulicity (dulaglutide)**
- **Precose (acarbose)**
- **Glyset (miglitol)**
- **Byetta, Bydureon (exenatide)**
- **Victoza (liraglutide)**
- **Ozempic(semaglutide)**
- **Adlyxin (lixisenatide)**

Will concomitant therapy with any of the following medications be discontinued? (Please Circle)
- **Trulicity (dulaglutide)**
- **Precose (acarbose)**
- **Glyset (miglitol)**
- **Byetta, Bydureon (exenatide)**
- **Victoza (liraglutide)**
- **Ozempic(semaglutide)**
- **Adlyxin (lixisenatide)**

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

_____

_____

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ Date: _____

FAX THIS FORM TO: 800-424-7640
MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP - 4201
P.O. Box 64811
St. Paul, MN 55164-0811